Vimarsana
Biggest News Aggregation in the World

Page 6 - Medication Guidefor News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Medication Guidefor. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Medication Guidefor Today - Breaking & Trending Today

Johnson & Johnson : Real-World Study Confirms Benefit of XARELTO® (rivaroxaban) for Secondary Prevention of Venous Thromboembolism in Cancer Patients - Vimarsana News

Johnson & Johnson : Real-World Study Confirms Benefit of XARELTO® (rivaroxaban) for Secondary Prevention of Venous Thromboembolism in Cancer Patients

Published: December 9, 2022

TITUSVILLE, NJ, December 9, 2022 - The Janssen Pharmaceutical Companies of Johnson & Johnson today announced observational data from eight years of clinical practice showing that... | December 9, 2022

Source: marketscreener.com
Related Topics:
United StatesLee PasqualoniCraigi ColemanAmerican Heart AssociationJanssen Pharmaceuticals IncJanssen Pharmaceutical CompaniesJanssen Pharmaceutical Companies Of JohnsonCardiovascular Metabolism At Janssen Scientific AffairsUniversity Of ConnecticutAmerican Society Of HematologyJanssen Scientific AffairsJanssenusand Janssen Scientific AffairsNational Blood Clot AllianceCenters For DiseaseNone Of The Janssen Pharmaceutical CompaniesSchool Of PharmacyExchange CommissionCompanies Of JohnsonObservational StudyCancer Associated ThrombosisAmerican SocietyAnnual MeetingAvery InceVice PresidentMedical Affairs
New TREMFYA® (guselkumab) Post-Hoc Analysis Reveals Active Psoriatic Arthritis Patients With Early Efficacy Had Meaningful Long-Term Improvement in Health-Related Quality of Life - Vimarsana News

New TREMFYA® (guselkumab) Post-Hoc Analysis Reveals Active Psoriatic Arthritis Patients With Early Efficacy Had Meaningful Long-Term Improvement in Health-Related Quality of Life

Published: November 10, 2022

Post-hoc analysis of DISCOVER-2 Phase 3 data suggest active psoriatic arthritis patients with week 8 response to TREMFYA showed meaningful improvements in...

Source: prnewswire.com
Related Topics:
University Of WashingtonUnited StatesSpring HouseCraig StoltzPhilipj MeaseDonvitot CreakyjointsTerence RooneyZismand ComorbiditiesEuroqol Research FoundationJanssen Biotech IncMental HealthAmerican College Of RheumatologyJanssen Research DevelopmentJanssen Pharmaceutical CompaniesJanssen Pharmaceutical Companies Of JohnsonHealth Qual Life OutcomesImprovements In HealthJanssen Scientific AffairsNational Psoriasis FoundationSwedish Medical Center Providence StNone Of The Janssen Pharmaceutical CompaniesJoseph HealthHealth Assessment QuestionnaireEarly Clinical Improvement As Predictor Of HealthExchange Commission
Biogen Inc.: New Data at ECTRIMS 2022 Highlight Biogen's Commitment to Advancing Individualized Disease Management for People Living with MS - Vimarsana News

Biogen Inc.: New Data at ECTRIMS 2022 Highlight Biogen's Commitment to Advancing Individualized Disease Management for People Living with MS

Published: October 26, 2022

Final safety and efficacy results from the Phase 3 EVOLVE-MS-1 trial demonstrate decreases in disease activity and favorable tolerability for VUMERITY (diroximel fumarate) consistent with previous

Source: finanznachrichten.de
Related Topics:
Nordrhein WestfalenUnited KingdomMaha RadhakrishnanCharles WeissmannWalter GilbertHeinz SchallerAllison ParksMike HenckeDiroximel FumarateKenneth MurrayUnilabs Customer Satisfaction SurveyChild DevelopmentObservational ProgramUniversity BochumExchange CommissionOutcomes On Child DevelopmentEuropean UnionResearch In Multiple SclerosisEuropean Committee For TreatmentEuropean CommitteeMultiple SclerosisChief Medical OfficerEfficacy ResultsHighlight Patient Reported OutcomesAnalysis Shows Impact
New TREMFYA® (guselkumab) Data Show an Overall Clinical Response Rate of Approximately 80 Percent in a Phase 2b Induction Study of Adults with Moderately to Severely Active Ulcerative Colitis - Vimarsana News

New TREMFYA® (guselkumab) Data Show an Overall Clinical Response Rate of Approximately 80 Percent in a Phase 2b Induction Study of Adults with Moderately to Severely Active Ulcerative Colitis

Published: October 24, 2022

/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from the Phase 2b QUASAR Induction Study 1 in adults with...

Source: prnewswire.com
Related Topics:
United StatesSpring HouseBritish ColumbiaCraig StoltzBurrillb CrohnBrucee SandsJan WehkampAmerican College Of Gastroenterology Annual MeetingCrohn Colitis FoundationJanssen Research DevelopmentJanssen Pharmaceutical CompaniesJanssen Pharmaceutical Companies Of JohnsonAmerican College Of GastroenterologyJapan PharmaceuticalsNone Of The Janssen Pharmaceutical CompaniesNational Institutes Of HealthExchange CommissionIcahn School Of Medicine At Mount SinaiCompanies Of JohnsonEuropean Medicines AgencyDevices AgencyCanadian Agency For Drugs Technologies In HealthCrohn Colitis Foundation Of AmericaGastroenterology Annual MeetingAnnual Scientific Meeting
Living With Psoriatic Arthritis? Tips to Manage Your Symptoms - Vimarsana News

Living With Psoriatic Arthritis? Tips to Manage Your Symptoms

Published: July 30, 2022

(BPT) - Sponsored by Janssen

Source: floydct.com
Related Topics:
United StatesSoumyad ChakravartySenior DirectorStrategic LeadRheumatology Therapeutic AreaAbout FindingWorkout That FeelsFunctional AssessmentChronic Illness TherapyImportant Safety InformationMedication GuidePrescribing InformationMedication Guidefor